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IGF-2 Is a Mediator of Prolactin-Induced
Morphogenesis in the Breast
genetically manipulated and because its mammary
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complex set of endocrinological abnormalities and infer-Summary
tility (Binart et al., 2000; Ormandy et al., 1997).
Recently, we described the behavior of PrlR/ MECsThe mechanisms by which prolactin controls prolifera-
engrafted in the mammary fat pads of wild-type mice;tion of mammary epithelial cells (MECs) and morpho-
these fat pads had previously been cleared of endoge-genesis of the breast epithelium are poorly under-
nous epithelium (Brisken et al., 1999). When induced tostood. We show that cyclin D1/ MECs fail to proliferate
become pregnant, these chimeras completed mammaryin response to prolactin and identify IGF-2 as a down-
ductal elongation and side branching but failed to devel-stream target of prolactin signaling that lies upstream
op the alveoli that normally accompany late-stage preg-of cyclin D1 transcription. Ectopic IGF-2 expression re-
stores alveologenesis in prolactin receptor/ epithe- nancy. This behavior demonstrated that the defect in
lium. Alveologenesis is retarded in IGF-2-deficient alveologenesis derived from the inability of PrlR/ MECs
MECs. IGF-2 and prolactin receptor mRNAs colocalize to respond to the high levels of circulating Prl that are
in the mammary epithelium. Prolactin induces IGF-2 present late in pregnancy and hence reflected cell-
mRNA and IGF-2 induces cyclin D1 protein in primary autonomous behavior of MECs. In addition, the en-
MECs. Thus, IGF-2 is a mediator of prolactin-induced grafted PrlR/ epithelium in these mice failed to differ-
alveologenesis; prolactin, IGF-2, and cyclin D1, all of entiate properly into milk-secreting cells. Together,
which are overexpressed in breast cancers, are com- these observations indicated that Prl signaling directly
ponents of a developmental pathway in the mammary controls both the increase in MEC number during alveo-
gland. logenesis and the differentiation of alveolar MECs into
milk-secreting cells.
Although the anterior lobe of the pituitary gland nor-Introduction
mally produces the bulk of Prl in the female body, the
hormone is also synthesized locally in the breast epithe-The systemic hormones estrogen, progesterone, and
lium (Reynolds et al., 1997). Local Prl synthesis as wellprolactin (Prl) control cell proliferation and morphogene-
as expression of the PrlR is upregulated within breastsis in the breast (Nandi, 1958). The cellular and molecular
carcinomas (Clevenger et al., 1995). While the physiolog-mechanisms underlying their growth-promoting func-
ical relevance of the local Prl secretion remains unclear,tions remain poorly understood. These hormones act
these observations suggest that localized deregulationdirectly on cells in the mammary gland and have indirect
of Prl signaling within the breast may contribute toeffects on this organ through their impact on other endo-
breast carcinogenesis. Consistent with this notion arecrine tissues.
observations that blocking Prl signaling interferes withThe mouse provides a suitable model system with
the growth of various breast cancer cell lines (Fuh andwhich to study the regulation of growth and differentia-
Wells, 1995; Ginsburg and Vonderhaar, 1995), and thattion of the breast, both because this animal can be
mice lacking the Prl gene show a delay in polyoma mid-
dle-T antigen-induced breast tumorigenesis (Vomachka5Correspondence: cathrin.brisken@isrec.unil.ch
et al., 2000).6Present address: Swiss Institute for Experimental Cancer Research,
Ch. des Boveresses 155, 1066 Epalinges, Switzerland. Prl acts as a potent mitogen and morphogen on the
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Figure 1. Response of Cyclin D1/ Mam-
mary Epithelium to Progesterone and Pro-
lactin
Cyclin D1/ and Cyclin D1/ MECs were en-
grafted to the cleared fat pads of 3-week-
old females. Eight weeks later, the recipients
were stimulated for 10 days with either pro-
gesterone, left panels, or Prl, right panels.
Shown are wholemount preparations of the
engrafted mammary glands. Note that both
grafts respond to progesterone stimulation
with extensive side branching but differ in
their response to Prl; the wt epithelium shows
extensive alveolar development, which is ab-
sent from the Cyclin D1/ graft. Identical re-
sults were obtained with six successfully en-
grafted mice in each group. Left bar, 500 m;
right bar, 400 m.
mammary epithelium in vivo (Nandi, 1958), but the mech- morphogenetic step and associated proliferation occur
normally in response to progesterone stimulation. Weanisms by which it induces cell proliferation remain un-
clear. To gain further insight into the mechanisms under- note here that in the course of conducting a large series
of experiments, we have never observed alveologenesislying Prl function in vivo, we conducted a screen that
selects specifically for genes that function downstream when wt mice of this genetic background are treated in
this way. However, when stimulated with Prl, the wtof the PrlR. Our findings indicate that an extracellular
factor, IGF-2, acts as a downstream mediator of PrlR grafts (Figure 1, bottom right) developed alveolar struc-
tures, which failed to form in the cyclin D1/ graftssignaling and upstream regulator of cyclin D1 expres-
sion. These results provide a route by which Prl can (Figure 1, top right). We concluded that cyclin D1 func-
tion is required to enable MECs to respond to the mor-act in a mitogenic fashion during alveologenesis and
carcinogenesis and links Prl signaling, IGF-2, and cyclin phogenetic effects of Prl. On the other hand, respon-
siveness to progesterone is unaffected by the absenceD1 expression, all of which are deregulated during tu-
morigenesis, to a common signaling pathway. of cyclin D1 in MECs. With these observations in mind,
we undertook to study the signaling pathway through
which Prl acts to trigger alveologenesis.Results
Response of cyclin D1/ Epithelium Screening for Prl Target Genes
We initially sought to determine the signaling mecha-to Pregnancy Hormones
cyclin D1/ female mice fail to lactate due to a develop- nism by which the ligand-activated PrlR is able to induce
cyclin D1 synthesis in MECs. Control experiments (Fig-mental defect in the mammary gland (Fantl et al., 1995;
Sicinski et al., 1995), which is intrinsic to the mammary ure 2A) showed that direct application of Prl to cultured
wt MECs induced relatively little cyclin D1 synthesisepithelium (Fantl et al., 1999). Both Prl and progesterone
are implicated in specific stages of mammary gland mor- within 8 hr when compared to the actions of a series of
growth factors such as epidermal growth factor (EGF),phogenesis during pregnancy, a time when the cyclin
D1/phenotype becomes apparent. To determine hepatocyte growth factor (HGF), and insulin. The pres-
ence of an intact Prl-PrlR signaling system in these cellswhether the morphogenetic and mitogenic effects of
either of these hormones were dependent on cyclin D1 was indicated by the successful induction of -casein
mRNA following exposure to Prl (data not shown). To-function, we established either cyclin D1/ or wild-type
(wt) MECs as grafts in the mammary stroma of wt hosts gether, these observations suggested that the mecha-
nisms controlling cyclin D1 transcription were intact incleared of the endogenous epithelium. Subsequently,
the recipients were treated with either Prl or progester- these cultured MECs and that it was unlikely that the
PrlR signals directly to the controllers of cyclin D1 tran-one for 10 days, and the responses of the transplanted
cells were assessed by wholemount microscopy. Pro- scription via an intracellular signaling cascade.
We reasoned that an alternative signaling mechanismgesterone was administered to ovariectomized female
mice by daily injections (Lydon et al., 1995). To achieve might involve the Prl-induced synthesis of some inter-
mediary signaling molecule that, once produced, pro-stably elevated blood levels of the short-lived Prl, we
resorted to using transplants of pituitary glands from ceeds to induce cyclin D1 synthesis. Consistent with
this model were our observations that cyclin D1 protein,adult mice of the same genetic background engrafted
under the kidney capsule of the host. This ectopic local- while only weakly induced 8 hr after Prl exposure (Figure
2A), was significantly induced 18 hr after stimulation ofization of the pituitary gland causes a selective increase
in Prl levels similar to those seen during pregnancy dur- growth factor-deprived primary MECs with Prl (Figure
2B). To explore the possible involvement of such aning the first 10 days after transplant (Huseby et al., 1985).
As shown in Figure 1, left panels, the cyclin D1/ and intermediary signaling molecule, we compared the tran-
scription profiles of pairs of contralateral cleared mam-the wt MECs underwent extensive branching in re-
sponse to progesterone, indicating that this particular mary fat pads that had been reconstituted with PrlR/
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Figure 2. Establishing a Hierarchy between
Prl, IGF-2, and cyclin D1
(A) Regulation of cyclin D1 protein expression
in primary MECs. Primary MECs were growth
factor deprived for 36 hr and subsequently
stimulated with various mammotropic factors
for 8 hours: estradiol (20 nmol), R5020 (20
nmol), hydrocortisone (1 g/ml), Prl (5 g/ml),
insulin (10 g/ml), HGF hepatocyte growth
factor (10 ng/ml), and EGF epidermal growth
factor (5ng/ml). Cyclin D1 protein levels as-
sessed by Western blotting with anti-cyclin
D1 antibodies.
(B) Regulation of cyclin D1 protein expression
by Prl. Primary MECs were growth factor de-
prived for 36 hr and subsequently stimulated
with different concentrations of Prl for 18 hr.
Cyclin D1 protein levels assessed by Western
blotting with anti-cyclin D1 antibodies.
(C) PrlR/ and Cyclin D1/ mammary epithe-
lia: morphogenetic block and IGF-2 mRNA
expression levels. Mammary epithelium from
PrlR/ROSA26/ and Cyclin D1/ROSA26/
mice was engrafted to cleared inguinal fat
pads of 3-week-old females. Eight weeks
later, the recipients were mated, and at day
16.5 of pregnancy, the engrafted glands and
an unmanipulated gland were analyzed. Top
panels show glands subjected to X-gal stain-
ing and wholemounted. PrlR/ROSA26/
(left) and Cyclin D1/ROSA26/ epithelia
(center) show fully branched ductal systems
but lack alveoli. In contrast, the unmanipu-
lated wt gland (right) shows extensive alveo-
lar development. Bottom panels show IGF-2
mRNA expression in the mutant transplants:
RNA samples in three serial dilutions were
subjected to RT-PCR with IGF-2 (upper
panel) and -gal (lower panel) specific prim-
ers. Densitometry revealed that the IGF-2 signal is 30-fold increased in the Cyclin D1/ROSA26/versus the PrlR/ROSA26/ transplant. The
same results were obtained with three further pairs of engrafted mammary glands. Right panel: IGF-2 mRNA expression levels in engrafted
and control glands were also measured by Real Time PCR and normalized to mRNA levels of the epithelial marker Keratin 18. Results from
three different experiments were averaged and plotted. Y-axis: arbitrary units.
(D) IGF-2 expression in mammary glands engrafted with Cyclin D1 /ROSA26/ and Cyclin D1/ROSA26/ mammary epithelium harvested
at day 12.5 of pregnancy. Three serial dilutions of RNA from the engrafted glands were subjected to RT-PCR with IGF-2 (upper panel) and
-gal (lower panel) specific primers. The amplification products were subjected to agarose gel electrophoresis and visualized by ethidium
bromide staining. The same results were obtained with three further pairs of engrafted mammary glands.
(E) Cyclin D1 induction by IGF-2 and RANKL. Primary MECs were growth factor deprived for 36 hr and subsequently stimulated with RANKL,
IGF-2, or EGF and insulin for eight hours. Cyclin D1 protein levels assessed by Western blotting with anti-cyclin D1 antibodies.
MECs in one fat pad versus cyclin D1/ MECs in the grafting experiments were both derived from mice that
were also heterozygous for the ROSA26 transgeneother. The host mice were wt, and after engrafting, were
allowed to become pregnant. (Friedrich and Soriano, 1991) and hence expressed
-galactosidase (-gal) constitutively. This enzyme andAs described above and illustrated in Figure 2C, top
panels, the morphogenetic block shown by MECs of its mRNA served as internal controls to ensure that simi-
lar amounts of engrafted epithelia were being comparedthese two genotypes was very similar. Hence, these two
types of mammary glands, assayed at an identical day in these expression analyses. Serial dilutions of RNA
derived from a group of engrafted recipient mice at dayof pregnancy, are presumed to carry comparable num-
bers of cells in comparable states of proliferation. We 16.5 of pregnancy were reverse-transcribed and levels
of -gal expression were measured by semiquantitativereasoned that the only differences in gene expression
pattern between the mammary glands of these two ge- PCR. Three pairs of samples in which the contralateral
transplants showed comparable amounts of -gal ex-notypes should involve those genes that lie downstream
of PrlR signaling and upstream of cyclin D1 expression. pression were pooled for cRNA probe preparation and
hybridization on 6.5 K Affymetrix (B-chip) mouse expres-More specifically, we looked for genes that were ex-
pressed at high levels in the cyclin D1/ but were ex- sion arrays. This analysis was performed in duplicate.
Out of the 6,500 transcripts surveyed, 319 were ex-pressed at low or undetectable levels in the PrlR/
grafts. pressed at more than 3-fold higher levels in the cyclin
D1/ than in the PrlR/ grafts; 430 transcripts wereThe donor cyclin D1/ and PrlR/ MECs in these
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downregulated more than 3-fold. Previous observations cyclin D1/ and the wt counterpart becomes apparent.
As shown in Figure 2D, the expression levels of IGF-2had indicated that, in contrast to the PrlR/ epithelium,
the cyclin D1/ epithelium retains its ability to undergo mRNAs were comparable when normalized to -gal ex-
pression levels in the two glands, indicating that cyclindifferentiation as manifested by its ability to synthesize
milk proteins late in pregnancy (Fantl et al., 1999). In- D1 does not act to repress IGF-2 expression. Taken
together, these various observations led us to concludedeed, many genes encoding proteins secreted with the
milk or involved in milk production such as metabolic that IGF-2 expression in the MECs of pregnant mice is
strongly dependent on signals emanating from the PrlR.enzymes, calcium transport, and intracellular vesicular
trafficking genes were found to be differentially ex-
pressed, with their transcripts being found at far higher Effect of IGF-2 on Cyclin D1 Expression
levels in the fat pads engrafted with cyclin D1/ MECs While the above data indicated that the PrlR is required
than in the fat pads engrafted with PrlR/ MECs. In for the induction of IGF-2 by MECs, it did not reveal
addition, genes involved in signal transduction, the con- whether IGF-2, once synthesized, could proceed to in-
struction of the cytoskeleton, and the extracellular ma- duce cyclin D1 synthesis. To address whether cyclin
trix were preferentially expressed in the cyclin D1/ re- D1 expression is under the direct control of IGF-2, we
combinants. stimulated primary MECs that had been deprived of
An overview of the genes whose expression levels growth factors with IGF-2 and assessed cyclin D1 pro-
differed by more than 10-fold is given in Table 1. Among tein levels 8 hr later. We also stimulated the cells with
the secreted factors that were particularly highly ex- RANKL, a factor recently implied to be an important
pressed in the cyclin D1/ grafts was insulin-like growth mediator of cyclin D1 expression in the mammary gland
factor-2 (IGF-2), which was found at a level 13.2-fold (Cao et al., 2001). We observed that the extent of cyclin
higher in the glands engrafted with cyclin D1/ epithelia D1 induction is dependent on the concentration of IGF-2,
than in the counterparts engrafted with PrlR/ epithelia. amounting to a 6-fold increase at an IGF-2 concentration
The expression levels of another growth factor, HB-EGF, of 50 ng/ml. However, RANKL failed to induce cyclin D1
differed by 4.5-fold. protein synthesis in these cells (Figure 2E) when applied
To validate the initial findings, we assessed relative at the concentration that has been shown to activate
IGF-2 and HB-EGF expression levels in four additional downstream signaling in these cells (Cao et al., 2001).
matched pairs of engrafted glands by quantitative RT- This indicated that IGF-2 can directly upregulate cyclin
PCR. After normalization for -gal expression, IGF-2 D1 protein in MECs. Taken together, these observations
mRNA levels were consistently 12- to 30-fold higher in indicated that the PrlR is required for the synthesis of
the cyclin D1/ transplanted glands than in the PrlR/ IGF-2 by MECs and that this growth factor, once synthe-
counterparts (Figure 2C, bottom panels), whereas HB- sized and released from MECs, can act in an autocrine
EGF levels differed by about 3-fold (data not shown). or paracrine fashion to elicit cyclin D1 synthesis.
Other growth factors represented on the arrays such as
FGF1, FGF15, HGF, EGF, and TGF differed less than Role of IGF-2 in Mediating Prl Function
3-fold between the two types of chimeric glands. We The scheme proposed above implies that IGF-2 acts as
also extended our analysis to additional growth factors an important mediator of PrlR signaling during alveolo-
such as amphiregulin, IGF-1, and RANKL (receptor acti- genesis. In particular, these observations suggested
vator of NF-b ligand) that are not represented on the that Prl induces IGF-2 and that the latter induces cyclin
arrays but are developmentally regulated in the mam- D1 synthesis, enabling alveologenesis to proceed. This
mary gland. We found no difference in their expression thinking prompted us to determine the role of IGF-2 as
levels between contralateral grafts (data not shown). a possible mediator of Prl-induced alveologenesis. More
This indicated that the strongest upregulation of the specifically, we asked whether ectopic expression of
growth factors tested was that of IGF-2. Taken together, IGF-2 could rescue the defect in alveologenesis ob-
these data provided evidence that IGF-2 synthesis in served in MECs lacking the PrlR and thus lacking Prl
MECs is under the control of the PrlR and thus Prl. signaling.
To test this notion, we infected MECs derived from 10-
week-old PrlR/ female mice of 129SV/C57Bl6 mixedRole of Cyclin D1 in Regulating IGF-2 Expression
Our screen was based on the assumption that those genetic background with a retrovirus expressing IGF-2.
The resulting cultures, a mixture of infected and nonin-genes that were expressed at higher levels in the fat
pads reconstituted with cyclin D1/ epithelium than in fected MECs, were used to reconstitute cleared mam-
mary fat pads of 3-week-old wt female mice. Previousthe fat pads reconstituted with PrlR / epithelium are
transcriptionally activated by Prl signaling. It was, how- work had shown that infection of MECs with a retrovirus
expressing -gal does not affect in vivo morphogenesisever, formally possible that the difference in IGF-2 gene
expression levels was independent of Prl signaling and (Edwards et al., 1996). This indicated that use of a ret-
roviral vector per se would have no effect on alveologen-resulted instead from a lack of repression in cyclin
D1/grafts. To address this possibility, we assessed esis. As a positive control, we determined whether the
alveologenesis phenotype of the PrlR/ MECs could beIGF-2 mRNA expression levels in the contralateral mam-
mary glands of a wild-type host that had been cleared rescued by infection with a retrovirus vector expressing
the PrlR. Eight weeks after injecting these MECs intoand reconstituted with either cyclin D1/ROSA26/ epi-
thelium or cyclin D1/ROSA26/ epithelium. We as- cleared fat pads, host mice were mated, and the mam-
mary glands of the resulting pregnant mice were ex-sessed a sample at day 12.5 of pregnancy before the
time when the morphological difference between the amined.
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Table 1. Putative Prolactin Target Genes
Genes Related to Milk Secretion
X93037 M. musculus mRNA for WDNM1 protein
W18308 Mouse ferritin heavy chain gene
x04673 Adipsin
X61431 ACYL-COA-BINDING PROTEIN
W44201 Sim. to PROTEIN TRANSPORT PROTEIN SEC23
Y00516 Mouse mRNA for aldolase A:FRUCTOSE-BISPHOSPHATE ALDOLASE A
M32599 Mouse glyceraldehyde-3-phosphate dehydrogenase mRNA
AA071776 Sim. to GLUCOSE-6-PHOSPHATE ISOMERASE (PHOSPHOGLUCOSE ISOMERASE)
J05277 Mouse hexokinase mRNA
x04490 Casein beta
L09104 M. musculus glucose phosphate isomerase mRNA, 3 end
M21285 Mouse stearoyl-CoA desaturase gene
AA117004 Sim. to ER LUMEN PROTEIN RETAINING RECEPTOR (KDEL RECEPTOR) (P23)
x02520 Lactate dehydrogenase 1, A chain




W20937 Sim. to CALCIUM-TRANSPORTING ATPASE SARCOPLASMIC RETICULUM TYPE
Cytoskeleton
x51438 Vimentin
AA168865 Sim. to ACTIN 1 (FRAGMENT)
X13297 ACTIN, AORTIC SMOOTH MUSCLE
J04953 Mouse gelsolin gene
X14425 Mouse mRNA for profilin:PROFILIN I
U20365 M. musculus smooth muscle gamma actin mRNA
Growth Factors
AA002605 Mouse insulin-like growth factor II (IGF-II) gene, 5 flank
Extracellular Matrix
X04017 Mouse mRNA for cysteine-rich glycoprotein SPARC
x14194 Nidogen
x17069 Mouse COL1A2 mRNA for pro-alpha-2(I) collagen
x65582 Procollagen, type VI, alpha 2
U08020 M. musculus alpha 1 type I collagen gene, partial cds and 3 flanking region
ET61037 Lectin, galactose binding, soluble 1
x72862 M. musculus gene for beta-3-adrenergic receptor::Adrenergic receptor, beta 3
X73523 Mouse mRNA for matrix Gla protein (MGP)
W75072 Procollagen, type IX, alpha 2
Signal Transduction
x15358 Sim. to INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4 PRECURSOR (IGFBP-4)
W65899 Sim. to GUANINE NUCLEOTIDE-BINDING PROTEIN G(I)/G(S)/G(T) BETA SUBUNIT 2
D10024 Mouse mRNA for protein-tyrosine kinase substrate p36 (calpactin I heavy chain)
X58251 M. musculus mRNA for E-selectin ligand-1
L23108 M. musculus mRNA for GTP-binding protein
X85788 M. musculus mRNA for DCC tumour suppressor
L09192 Cathepsin D
M16358 RAB1, member RAS oncogene family
Heat Shock
AA163643 Sim. to HEAT SHOCK COGNATE 71 KD PROTEIN
U73744 M. musculus heat shock 70 protein (Hsc70) gene
AA105022 Sim. to HEAT SHOCK PROTEIN HSP 90-BETA (HSP 84) (HSP 90)
Miscellaneous
W41817 M. musculus cytochrome c oxidase subunit VIII precursor (Cox81) mRNA
Z83368 M. musculus RPS3a gene
M76131 Mouse elongation factor 2 (ef-2) mRNA, 3 end
AA154007 Sim. to POL POLYPROTEIN; REVERSE TRANSCRIPTASE
X05021 Murine mRNA with homology to yeast L29 ribosomal protein gene
x54691 Cytochrome C oxidase, subunit IV
W88176 Sim. to THIOL-SPECIFIC ANTIOXIDANT PROTEIN (PRP)
Z50159 M. musculus mRNA for Sui1
M24263 Mouse testosterone 16-alpha-hydroxylase (CB) gene
AA138107 Mouse COX7c1 mRNA for cytochrome c oxidase VIIc (EC 1.9.3.1)
D00466 Mouse apolipoprotein E mRNA
x82067 M. musculus thioredoxin-dependent peroxide reductase (tpx) mRNA
Genes expressed at more than 10-fold higher levels in mammary glands engrafted with cyclin DI/ than with PrlR/ mammary epithelium,
as assessed by microarray analysis.
Developmental Cell
882
Figure 3. Rescuing the Morphogenetic Defect of PrlR/ Epithelium by Ectopic Expression of IGF-2
MECs derived from PrlR/ROSA26/ female mice were infected with retroviruses expressing either the PrlR (C) or IGF-2 (D,E,G, and I) or
mock infected (B, F, and H) and subsequently engrafted into the cleared fat pads of 3-week-old females. The recipients were impregnated.
At the end of pregnancy the engrafted glands and thoracic mammary gland were analyzed by X-gal staining and subsequent wholemount
microscopy (top panels).
(A) Unmanipulated gland displays extensive alveolar development.
(B) Mock-infected PrlR/ epithelium devoid of alveolar structures.
(C) PrlR/ epithelium infected with PrlR retrovirus showing a sector with alveolar development within a ductal system devoid of alveolar
structures. Note that the alveoli are as distended as in the wt control, indicating that the epithelium lining them displays secretory activity.
(D and E) PrlR/ epithelium infected with IGF-2 retrovirus showing a sector containing alveolar structures within a ductal system devoid of
alveoli (D), or showing more extensive alveolar sprouting (E). Note: outpouchings are not distended, suggesting that the epithelium lining them
is not actively secreting.
(F–I) H&E stained histological sections of mock-infected (F and H) and IGF-2-infected (G and I) PrlR/ epithelium. Note the increase in MEC
number caused by ectopic IGF-2 expression (G versus F) and the similarity of the outpouchings formed (G and I) to alveoli seen at mid
pregnancy (Figure 4, bottom right panel).
Retrovirus-mediated expression of the PrlR in the PrlR/MECs could be rescued with an IGF-2-expressing
retrovirus vector. As shown in Figures 3D and 3E, thePrlR/ROSA26 / MECs enabled alveolar development
to occur in discrete sectors of the reconstituted glands ectopic expression of IGF-2 in PrlR/ MECs led to the
development of multiple out-pouchings of the mammary(Figure 3C). In contrast, engrafted PrlR/ROSA26/
MECs that were not exposed to the PrlR retrovirus and ductal tree. Histological analysis of PrlR/ grafts (Fig-
ures 3F and 3H) and PrlR/ epithelia ectopically ex-used as a negative control in this experiment (Figure
3B) developed into a highly branched ductal tree that pressing IGF-2 (Figures 3G and 3I) further illustrate the
increase in epithelial cell number caused by IGF-2 andcompletely lacked alveoli, as shown previously (Brisken
et al., 1999). Moreover, an unmanipulated thoracic gland show that the resulting structures closely resemble nor-
mal alveoli at mid-pregnancy (see Figure 4, right bottomof these recipient mice (Figure 3A) used as a positive
control shows extensive alveolar development, typical panel). However, in contrast to the alveolar structures
seen in the mutant epithelium rescued by the PrlR, theseof late-stage pregnancy. As anticipated, the alveoli in
this unmanipulated gland are fully distended, indicating out-pouchings of the mammary ductal tree failed to ex-
pand, indicating that the cells lining the alveoli werethat the cells lining them are differentiated and actively
secreting milk products. The alveolar structures whose not actively secreting milk products and were thus not
terminally differentiated. We concluded that IGF-2 canformation has been rescued by the retroviral PrlR vector
were as dilated as the alveoli formed in the thoracic indeed function as an important downstream mediator
of Prl’s morphogenetic effects, whereas it does notgland of the host (Figure 3A), implying that these struc-
tures are secreting milk products. Thus, both the mor- make any discernible contribution to the differentiation
of MECs leading to milk production and secretory ac-phogenetic as well as the differentiative effects of Prl
signaling could be rescued by ectopic expression of the tivity.
When wt MECs infected with the IGF-2 retrovirus werewt PrlR in the previously PrlR/MECs.
We next determined whether the defects of the used to reconstitute cleared fat pads of wt hosts, no
IGF-2 Mediates Prolactin Function in the Mammary Gland
883
Figure 4. Function of IGF-2 in the Mammary Epithelium in Mid/Late Pregnancy.
Mammary epithelium from IGF-2/ and IGF-2/ mice was engrafted to the cleared inguinal fat pads of 3-week-old F1 (129SV/C57Bl6) females.
Eight weeks after surgery, the recipients were impregnated and their mammary glands were harvested at day 14.5 and analyzed by wholemount
preparation (top panels) and subsequent histological sectioning and H & E staining (bottom panels). Mutant graft (left panels) shows less
alveolar development than contralateral wt graft (central panels) and an unmanipulated gland of the recipient (right panels). The result is
representative of ten pairs of grafts analyzed at this stage of pregnancy. Scale bar: top panels, 1 mm; bottom panels, 100 m.
difference to the endogenous glands was noticed upon alveolar development than the wt counterparts at day
14.5 of pregnancy as assessed by wholemount micros-wholemount analysis (data not shown) in over 20 such
grafts. This indicates that constitutive expression of copy (Figure 4, top panels) and histological analysis
(Figure 4, bottom panels). However, by the end of preg-IGF-2 itself is not sufficient to induce alveologenesis but
does so only in the context of other changes induced nancy, the contralateral transplants were indistinguish-
able (data not shown). Hence, the absence of IGF-2by pregnancy.
compromises the ability of Prl to induce alveologenesis
in mid-pregnancy, but it appears that other factors sub-Role of Endogenous IGF-2 Expression
in Mammary Gland Development sequently elicited by Prl compensate for this defect in
the later stages of pregnancy.To further assess the functional role of endogenous
IGF-2 expression in the mammary epithelium, we deter-
mined whether the absence of IGF-2 expression in MECs Localization of PrlR and IGF-2 mRNA Expression
in the Mammary Epitheliumwould also impair development of the mammary epithe-
lium. To address this question, we procured mice that To gain further insight into the connection between Prl
signaling and IGF-2 synthesis, we assessed the localiza-carried an inactivated germline allele of IGF-2 (DeChiara
et al., 1990). The IGF-2 gene is paternally imprinted in tion of PrlR and IGF-2 mRNA expression by in situ hy-
bridization of mammary glands at different develop-mammals and, as expected, females that inherit the
mutant allele from their father show no expression of mental stages. As shown in Figure 5, in the virgin female
there was substantial expression of the PrlR mRNA inIGF-2 in their mammary tissue (data not shown), an ab-
sence that had previously been reported in other tissues the luminal compartment of the mammary epithelium.
Expression of IGF-2 mRNA was barely detectable at this(DeChiara et al., 1990, 1991). The IGF-2-depleted ani-
mals are initially growth retarded but breed normally, stage. In contrast, at day 12.5 of pregnancy, the IGF-2
mRNA-related signal was intense and was colocalizedand the mutant females nurse their pups (DeChiara et
al., 1990, 1991), indicating that mammary gland develop- with the PrlR mRNA signal in the luminal layer of MECs
in the mammary epithelium. At day 16.5 of pregnancy,ment is not severely impaired in the absence of IGF-2
expression. Nonetheless, it remained possible that the both mRNAs were found in the newly formed alveolar
structures. We concluded that the localization of theseabsence of IGF-2 significantly affected mammary epi-
thelial morphogenesis during pregnancy. two transcripts is consistent with a mechanism in which
IGF-2 expression is induced by Prl stimulation of theTo assess this possibility, we transplanted IGF-2-
depleted and wt MECs into cleared contralateral fat same or nearby MECs.
pads of wt hosts and assessed alveologenesis during
a subsequent pregnancy. A series of three experiments, Regulation of IGF-2 Expression by Prolactin
To test whether IGF-2 expression is indeed controlledcomprising a total of ten pairs of grafts, revealed that
the IGF-2 mutant epithelium showed consistently less by Prl, primary wt MECs in culture were stimulated with
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Figure 5. Coexpression of PrlR and IGF-2 mRNAs in the Luminal Compartment of the Mammary Epithelium
Mammary glands were harvested from a virgin adult female mouse and from mice at days 12.5 and 16.5 of pregnancy. The glands were
processed for in situ hybridization; adjacent sections were hybridized with 35S-labeled antisense cRNA probes for PrlR or IGF-2 and exposed
for 6 days. H&E stained sections are shown next to the corresponding dark-field exposures. Both PrlR and IGF-2 mRNA expression localizes
to the luminal epithelium. Light green areas represent the dense fibrous stroma surrounding the ducts. Scale bar: 150 m.
Prl, and IGF-2 mRNA expression levels were measured locally produced, secreted factor that appears to operate
in a paracrine manner to encourage MEC proliferation.at various time points by real-time PCR. IGF-2 mRNA
levels increased 2-fold within 2 hr of Prl exposure, 15- These findings suggest a model in which the Prl-medi-
ated induction of IGF-2 in PrlR-positive MECs providesfold at 16 hr, and were 30-fold elevated by 72 hr (Figure 6,
top). By contrast, expression of RANKL mRNA remained an amplification of the initial Prl signal by broadcasting
it via paracrine signaling to nearby MECs. This may serveconstant. To test whether the induction is specific to Prl,
we analyzed IGF-2 and RANKL levels in progesterone- to coordinate proliferation among the MECs participat-
ing in the formation of an alveolus and also may createstimulated mammary glands. RANKL was induced 80-
fold, whereas IGF-2 expression remained unchanged a means for sustaining the Prl stimulus over an extended
period of time, even when Prl levels have declined, as(Figure 6, bottom). Thus, Prl can specifically induce
IGF-2 expression in MECs through a direct mechanism often occurs because of pulsatile secretion of this hor-
mone (Horseman, 2001).not involving other cell types present in the mammary
gland. In the same cells, RANKL expression is positively The closest relative of the PrlR—the growth hormone
receptor—responds to ligand by inducing IGF-1 secre-regulated by progesterone rather than Prl signaling.
tion, and the latter serves to mediate some of its down-
stream effects (Cohen and Rosenfeld, 1996). This cre-Discussion
ates a striking parallel with the presently observed
behavior of the PrlR and IGF-2. It remains to be seenAlthough the role of hormones in breast carcinogenesis
is widely recognized, in vitro studies are limited to breast whether IGF-2 mediates Prl signaling functions in vari-
ous organs throughout the body or whether its role iscarcinoma cell lines (Brockman et al., 2002; Das and
Vonderhaar, 1996; Schroeder et al., 2002), and the pre- limited to the mammary gland.
IGF-1, IGF-2, several IGF binding proteins and thecise mechanisms by which hormones control prolifera-
tion and differentiation of MECs in vivo remain largely IGF-1R have all been shown to be expressed in the
mammary gland (Wood et al., 2000). IGF-1 has beenunknown. Here, we identify IGF-2 as a downstream me-
diator of PrlR morphogenetic signaling and an upstream found to mediate the actions of growth hormone and to
cooperate with estrogen to promote ductal develop-regulator of cyclin D1 expression. This links Prl signaling,
IGF-2, and cyclin D1 expression, all of which are deregu- ment (Kleinberg, 1998). In accord with such a role, IGF-
1R/ MECs transplanted to the cleared mammary fatlated during breast carcinogenesis in humans, to a com-
mon developmental signaling pathway, i.e., Prl → of a wt host shows impaired ductal outgrowth but a
normal response to pregnancy hormones (Bonnette andIGF-2 → cyclin D1.
Our data have revealed that, unexpectedly, Prl does Hadsell, 2001). Hence this pathway is involved in a dis-
tinct step of mammary morphogenesis that occurs be-not act directly on intracellular mitogenic regulatory
pathways but triggers instead proliferation through a fore those that are regulated by Prl and progesterone.
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Figure 6. Induction of IGF-2 mRNA Expres-
sion in MECs by Prolactin
MECs were stimulated with Prl (5 g/ml) and
RNA was harvested at different time points
and reverse-transcribed. The cDNA was am-
plified with Keratin 18-, IGF-2-, and RANKL-
specific primers and the products quantified
by real time PCR. The graph shows relative
IGF-2 expression after normalization for Ker-
atin 18, values are in triplicates, representa-
tive of four different experiments.
Eight 10-week old wt females were ovariecto-
mized. After 20 days, they were injected with
200 ng estradiol. Twenty-four hours later, four
of them were injected with 2 mg progesterone
(P); the other four received vehicle only (con-
trol). Eight hours later, the mammary glands
were harvested, and RNA was extracted and
reverse-transcribed. The cDNA was amplified
with Keratin 18-, IGF-2-, and RANKL-specific
primers and the products quantified by real
time PCR. Shown is relative IGF-2 and RANKL
expression after normalization for Keratin 18.
The signaling pathway elucidated here may play an transcriptional promoters being activated with distinct
kinetics.important role in the pathogenesis of many breast can-
cers. Thus the anti-apoptotic/mitogenic signal provided We have shown that cyclin D1 is required specifically
for Prl-induced morphogenesis of the ductal epitheliumby IGF-2 expression appears to be constitutively active
in tumors expressing high levels of IGF-2 (McCann et and that IGF-2 functions as an intermediary between
the two, being capable of inducing cyclin D1 on its own.al., 1996). When viewed in terms of its effects aiding
tumor progression, this IGF-2 expression may obviate Whether the increase in cell number seen in the course
of IGF-2 induced alveologenesis is due to increasedthe need for deregulation of other components of this
pathway, notably Prl itself. Indeed, IGF-2, its cousin proliferation, decreased apoptosis or both remains to be
assessed. Significantly, studies comparing IGF-2 mRNAIGF-1 (Cullen et al., 1992), and two receptors activated
by both factors, the IGF-1R (Baserga et al., 1997; Sur- expression with the pattern of BrdU-labeled cells during
mid-pregnancy (Richert and Wood, 1999) suggest thatmacz et al., 1998) and the insulinR (A form) (Morrione
et al., 1997), are all found to be overexpressed in certain IGF-2 may function as a mitogen for MECs. However, in
the context of mammary epithelial involution occurringbreast carcinomas (Pandini et al., 1999; Sciacca et al.,
1999). during weaning, ectopically expressed IGF-2 has been
found to exert anti-apoptotic effects (Moorehead et al.,The IGF-2 gene has five promoters, which are used in
a tissue-specific (Gray et al., 1987) and developmentally 2001). The fact that constitutive IGF-2 expression shows
a striking capacity to rescue the morphogenetic defectregulated fashion (Schofield and Tate, 1987). A search
of the regulatory upstream region with MatInspector of PrlR/ MECs without rescuing the ability of the mu-
tant epithelium to produce milk is consistent with aV2.2/Transfac 4.0 (Quandt et al., 1995) revealed 44 con-
sensus STAT binding sites, compatible with a model in model whereby Prl induces morphogenesis through
IGF-2 and cyclin D1 expression and controls differentia-which Prl induces IGF-2 transcription through STAT5
activation. However, we find that in mammary glands tion through a second, distinct downstream signaling
pathway.engrafted with STAT5ab/ epithelia, IGF-2 levels are
comparable to those seen in wt mammary glands. More While constitutive expression of IGF-2 is sufficient to
rescue the morphogenetic defect of PrlR/ MECs, it isgenerally, the functional significance of these particular
IGF-2 promoter sites remains unclear, and the specific clearly not the only Prl-induced growth/survival factor
that can do so. The retardation in alveologenesis seenidentities of the promoters used during breast develop-
ment and tumorigenesis remain to be established. Our in mid-pregnancy in IGF-2-depleted epithelia is reversed
later in pregnancy, ostensibly by the compensatory ac-finding that the induction of IGF-2 by Prl goes from
2-fold during the first 10 hr to a 60-fold increase by 72 tions of other, still-unknown factors. An attractive candi-
date here is HB-EGF, whose synthesis we find also tohr of Prl stimulation is compatible with different IGF-2
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IGF-2 F, GTGCGGAGGGGAGCTTGTTGAC; IGF-2 R, GTGGbe dependent on PrlR action, albeit to a lesser extent.
GCGTCTTTGGGTGGTA; RANKL F TGTACTTTCGAGCGCAGATG;The FGF signaling pathway has also been implicated to
RANKL R, CCCACAATGTGTTGCAGTTC.play an important role in alveologenesis (Jackson et al.,
1997), and there is evidence that the Wnt pathway acting
In Situ Hybridizationvia cyclin D1 (Hsu et al., 2001; Imbert et al., 2001) may be
In situ hybridization was as described (Das et al., 1994). Frozen
involved. It is conceivable that certain genes encoding sections were hybridized with 35S-labeled antisense or sense cRNA
molecules linked to these regulatory pathways were probes for PrlR or IGF-2 for 4 hr at 45C and exposed for 6 days.
missed in our screen, which surveyed an arbitrary subset
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